Depression

Pirandamine free base is a selective serotonin (5-HT) (HY-B1473A) uptake inhibitor with an IC₅₀ of 250 nM. It exerts antidepressant-like effects by enhancing central serotonergic function, does not inhibit norepinephrine (HY-13715) uptake, and exhibits no central anticholinergic or monoamine oxidase inhibitory activity. Pirandamine free base is used in the study of depression.

STOCK3S-30866 is a blood-brain barrier-permeable ligand of human serotonin transporter (hSERT) and leucine transporter (LeuT). STOCK3S-30866 has gastrointestinal absorption capacity and no mutagenic potential. STOCK3S-30866 can be used in research related to major depressive disorder.

(S)-Viloxazine ((S)-Viloxazin) is the more pharmacologically active isomer of Viloxazine (HY-W380450). (S)-Viloxazine is an orally active, blood-brain barrier penetrant norepinephrine transporter inhibitor. It also acts as a 5-HT2C receptor agonist and a 5-HT2B receptor inhibitor. (S)-Viloxazine modulates serotonergic and noradrenergic activities, blocks norepinephrine reuptake, and elevates extracellular levels of serotonin, norepinephrine and dopamine in the prefrontal cortex, without inhibiting 5-HT or dopamine uptake into synaptosomes. (S)-Viloxazine can be used in research related to attention deficit hyperactivity disorder and depression.

(±)-Selegiline (Deprenyl) is the racemic of Selegiline (HY-14198). Selegiline is a potent, selective and irreversible inhibitor of MAO-B, with an IC₅₀ of 51 nM. Selegiline exhibits 450-flod selectivity for MAO-B over MAO-A (IC₅₀=23 μM). Selegiline can be used for the research of Parkinson's disease, Alzheimer's disease and major depressive disorder.

Tofenacin hydrochloride (TOF hydrochloride) is an orally active weak anticholinergic compound. Tofenacin hydrochloride can be used to study extrapyramidal symptoms and depressive side effects associated with the use of Fluphenazine decanoate (HY-B1904) .

18-Methoxycoronaridine ((-)-18-Methoxycoronaridine) hydrochloride is an orally active and selective α3β4 nicotinic acetylcholine receptor (nAChR) antagonist. 18-Methoxycoronaridine hydrochloride is an inhibitor of serotonin transporter (SERT) and norepinephrine transporter (NET), with IC₅₀ values of 51.6 μM and 121 μM for SERT and NET, respectively. 18-Methoxycoronaridine hydrochloride inhibits the function of SERT and NET, promotes 5-HT3A receptor desensitization, blocks α3β4 nAChR, and modulates receptor signaling pathways associated with reinforcement. 18-Methoxycoronaridine hydrochloride also exhibits potent antiparasitic activity. 18-Methoxycoronaridine hydrochloride can be used in research related to depression, obesity, alcoholism, smoking addiction, and cutaneous leishmaniasis.

Gliquidone sodium (AR-DF 26 sodium) can bind to the pancreatic β-cells and increases insulin release to regulate blood glucose levels. Gliquidone sodium significantly decreases LPS (HY-D1056)-induced proinflammatory responses and inhibits ERK/STAT3/NF-κB phosphorylation in BV2 microglial cells. Gliquidone sodium can suppress microgliosis, microglial hypertrophy mediated by LPS, and proinflammatory cytokine COX-2 and IL-6 levels in murine model. Gliquidone sodium also exhibits good anticancer activity in lung carcinoma cells. Gliquidone sodium has antioxidant property. Gliquidone sodium can be studied in research for type 2 diabetes and cancers.

Dibenzepine is a blood-brain barrier permeable ligand of the histamine H1 receptor (Histamine H1 Receptor), with a K_i value of 0.02 μM. Dibenzepine exhibits varying degrees of affinity for multiple serotonin receptors and dopamine receptors. Dibenzepine can be used in research related to depression, schizophrenia, dementia, and non-specific agitation.

Netupitant hydrochloride (CID 6451149 hydrochloride) is a blood-brain barrier penetrable, orally active NK1 receptor inhibitor with a K_i of 0.95 nM (CHO cells) against the human receptor. Netupitant hydrochloride antagonizes the effects induced by Substance P, inhibits the maximal response of Substance P with a long-lasting action, and suppresses NK1 agonist-induced behaviors in mice and gerbils. Netupitant hydrochloride reduces the frequency of bladder contractions, prolongs contraction intervals, decreases basal pressure at high doses, and acts on the afferent branch of the micturition reflex. Netupitant hydrochloride can be used in research related to overactive bladder, chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, anxiety disorders, and depression.

(Z)-Doxepin is an isomer of Doxepin (HY-B0725A). Doxepin is an orally active, blood-brain barrier penetrant tricyclic antidepressant with multiple activities including hypnosis, sedation, analgesia and vasodilation. Doxepin enhances the expression of PSD-95 and synapsin 1 via the PI3K/AKT/mTOR signaling pathway, and is metabolized to Desmethyldoxepin in vivo. Doxepin can be used in research related to various diseases such as depression, anxiety, obesity and atopic dermatitis.

Panuramine is a blood-brain barrier permeable, orally active selective 5-HT Receptor antagonist with an IC₅₀ of 22 nM. Panuramine prevents 5-HT reuptake through non-competitive antagonism of 5-HT Receptor, but does not affect dopamine uptake. Panuramine can be used for research on depression.

Oxprenoate (RU 28318 (free base)) is an orally active, brain-penetrant selective mineralocorticoid receptor antagonist that blocks Aldosterone (HY-113313) signaling through competitive binding to MR, and exhibits anxiolytic and neuroprotective activities, as well as modulates Corticosterone (HY-B1618) levels. Oxprenoate is used in research on hypertension, anxiety disorders, depression, Alzheimer's disease, and glucocorticoid-related neuronal injury.

Azaphen free base (Azafen free base) is an orally active tricyclic antidepressant that inhibits the reuptake of serotonin and monoamines, regulates the 5-HT2c receptor, and exerts sedative, antidepressant and anxiolytic effects. Azaphen free base increases the bioavailability of serotonin in the synaptic cleft, does not block muscarinic receptors or affect monoamine oxidase activity, and binds to the human serotonin transporter via salt bridges, π-stacking, π-cation and hydrophobic interactions. Azaphen free base can be used in studies related to depression.

Tofacitinib-d₃ (Tasocitinib-d₃; CP-690550-d₃) is the deuterated-labeled Tofacitinib (HY-40354). Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury.

Tofacitinib-¹³C (Tasocitinib-¹³C; CP-690550-¹³C) is the ¹³C-labeled Tofacitinib (HY-40354). Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury.

Dexnafenodone ((S)-Nafenodone free base; LU-43706 free base) is a novel antidepressant candidate molecule that selectively inhibits the norepinephrine synaptosomal uptake transporter. Dexnafenodone inhibits the fast inward Na⁺ current and slow inward Ca²⁺ current in cardiomyocytes. Dexnafenodone inhibits voltage-gated and receptor-activated Ca²⁺ influx in vascular smooth muscle, depletes norepinephrine-sensitive intracellular Ca²⁺ stores, suppresses agonist-stimulated Ca²⁺ influx, relaxes precontracted vascular smooth muscle, inhibits spontaneous myogenic activity, and modulates cardiac electrophysiology, exerting negative chronotropic and negative inotropic effects. Dexnafenodone can be used in the research of depression.

Nemifitide diTFA (Standard) (INN 00835 diTFA (Standard)) is the analytical standard of Nemifitide diTFA (HY-105077A). This product is intended for research and analytical applications. Nemifitide diTFA (INN 00835 diTFA) is a 5-HT2A receptor ligand that crosses the blood-brain barrier. Nemifitide diTFA is used in research related to major depressive disorder.

2-(1-Piperazinyl)pyrimidine Standard is the analytical standard of 2-(1-Piperazinyl)pyrimidine (HY-W004464). This product is intended for research and analytical applications. 2-(1-Piperazinyl)pyrimidine is an orally effective α₂-adrenoceptor antagonist and 5-HT1A receptor agonist. 2-(1-Piperazinyl)pyrimidine is an in vivo metabolite related to buspirone. 2-(1-Piperazinyl)pyrimidine modulates excitatory synaptic transmission in the hippocampus and the release of monoamine transmitters such as norepinephrine and 5-HT by blocking α2-adrenoceptor and activating 5-HT1A Receptor. 2-(1-Piperazinyl)pyrimidine is used in research on psychiatric disorders such as anxiety and depression.

LuAF60097 is a serotonin transporter (SERT) ligand. LuAF60097 binds to the extracellular vestibule (S2 site) of SERT with high affinity and to the central binding site (S1) with lower affinity, triggering conformational changes that exert combined competitive and non-competitive inhibitory effects on serotonin reuptake. LuAF60097 is applicable to research related to depression and anxiety disorders.

Dexamisole hydrochloride ((+)-Tetramisole (hydrochloride)) is an orally active dextral tetramisole with mood-enhancing and mental tension-improving effects. Dexamisole hydrochloride can be used in studies related to neurotic depression or endogenous retarded depression.